Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIO-FD&C currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, COUGHLIN, DANIEL F, who also serves as the company's busiest examiner. The presence of only 1 pending action suggests a highly focused or early-stage prosecution phase for the company's current filings in this technical field.
The administrative oversight for this Biotechnology & Pharmaceuticals portfolio is limited to 1 distinct art unit. COUGHLIN, DANIEL F holds 1 busiest examiner pending action, which accounts for the entirety of the company's active office action volume. This relationship between the pending action, the examiner, and the art unit indicates a streamlined interaction with the patent office. Practitioners can expect a singular point of contact for the company's current Biotechnology & Pharmaceuticals matters, as the distinct examiner manages the only pending office action available in the data.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, DANIEL F | 1 | 38.9% | +18.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18680600 | MANUFACTURING METHOD OF COFFEE CELL AND ADVENTITIOUS ROOT CULTURE COMPRISING INCREASED BIOACTIVE SUBSTANCES AND USE THEREOF | COUGHLIN, DANIEL F | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18680600 | MANUFACTURING METHOD OF COFFEE CELL AND ADVENTITIOUS ROOT CULTURE COMPRISING INCREASED BIOACTIVE SUBSTANCES AND USE THEREOF | COUGHLIN, DANIEL F | 1619 | §103 | Non-Final OA | — | Pending | May 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIO-FD&C has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Daniel F Coughlin has the most, with 1 of BIO-FD&C's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
